FXN and Friedreich ataxia: Mice in which FXN is knocked out in astrocytes later in life develop no clear neurological phenotype, possibly showing the limits of frataxin re-introduction in astrocytes in mature animals.9 We believe that this review, through analysis of a more complete set of data derived from multiple techniques, provides a comprehensive summary of therapeutic targets in FRDA.